Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 3/20 | 0.36 |
| ▸ | MERTK | Q12866 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | DDX3X | O00571 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989884 | 1.00 | CHRM1 (0.42) | CHRM1KAT5RIPK2HRH3GCGR | |
| SCHEMBL15419934 | 0.90 | CHRM1 (0.40) | CHRM1KAT5RIPK2HRH3AXL | |
| SCHEMBL12989206 | 0.90 | CHRM1 (0.40) | CHRM1KAT5RIPK2HRH3AXL | |
| SCHEMBL15419935 | 0.90 | CHRM1 (0.40) | CHRM1KAT5RIPK2HRH3AXL | |
| SCHEMBL12989171 | 0.90 | CHRM1 (0.40) | CHRM1RIPK2HRH3GCGRAXL | |
| SCHEMBL15420585 | 0.90 | CHRM1 (0.40) | CHRM1RIPK2HRH3GCGRAXL | |
| SCHEMBL12989178 | 0.90 | CHRM1 (0.40) | CHRM1RIPK2HRH3GCGRAXL | |
| SCHEMBL15420612 | 0.88 | GCGR (0.44) | CHRM1RIPK2HRH3GCGR | |
| SCHEMBL15420531 | 0.86 | SYK (0.39) | CHRM1KAT5RIPK2AXLMERTK | |
| SCHEMBL15420260 | 0.86 | KAT5 (0.40) | CHRM1KAT5RIPK2HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2694472-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| WO-2012137982-A9 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-14 | — | — | WO | disclosed |
| WO-2012137982-A2 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | CHRM1 227/4885KAT5 2329/4885RIPK2 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.